Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 254

1.

FAM83A and FAM83B as Prognostic Biomarkers and Potential New Therapeutic Targets in NSCLC.

Richtmann S, Wilkens D, Warth A, Lasitschka F, Winter H, Christopoulos P, Herth FJF, Muley T, Meister M, Schneider MA.

Cancers (Basel). 2019 May 11;11(5). pii: E652. doi: 10.3390/cancers11050652.

2.

A retrospective cohort study of PD-L1 prevalence, molecular associations and clinical outcomes in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscape Project.

Kerr KM, Thunnissen E, Dafni U, Finn SP, Bubendorf L, Soltermann A, Verbeken E, Biernat W, Warth A, Marchetti A, Speel EM, Pokharel S, Quinn AM, Monkhorst K, Navarro A, Madsen LB, Radonic T, Wilson J, De Luca G, Gray SG, Cheney R, Savic S, Martorell M, Muley T, Baas P, Meldgaard P, Blackhall F, Dingemans AM, Dziadziuszko R, Vansteenkiste J, Weder W, Polydoropoulou V, Geiger T, Kammler R, Peters S, Stahel R; Lungscape Consortium.

Lung Cancer. 2019 May;131:95-103. doi: 10.1016/j.lungcan.2019.03.012. Epub 2019 Mar 15.

PMID:
31027705
3.

[Immunophenotyping of lung tumors : An update].

Warth A, Fink L.

Pathologe. 2019 Apr 1. doi: 10.1007/s00292-019-0589-0. [Epub ahead of print] Review. German.

PMID:
30937512
4.

Potential for the blood-based biomarkers cytokeratin 19 fragment (CYFRA 21-1) and human epididymal protein 4 (HE4) to detect recurrence during monitoring after surgical resection of adenocarcinoma of the lung.

Muley T, He Y, Rolny V, Wehnl B, Escherich A, Warth A, Stolp C, Schneider MA, Meister M, Herth FJ, Dayyani F.

Lung Cancer. 2019 Apr;130:194-200. doi: 10.1016/j.lungcan.2019.02.017. Epub 2019 Feb 19.

5.

E3 ubiquitin ligase Smurf2: a prognostic factor in microsatellite stable colorectal cancer.

Klupp F, Giese C, Halama N, Franz C, Lasitschka F, Warth A, Schmidt T, Kloor M, Ulrich A, Schneider M.

Cancer Manag Res. 2019 Feb 22;11:1795-1803. doi: 10.2147/CMAR.S178111. eCollection 2019.

6.

Agreement of CK5/6, p40, and p63 immunoreactivity in non-small cell lung cancer.

Kriegsmann K, Cremer M, Zgorzelski C, Harms A, Muley T, Winter H, Kazdal D, Warth A, Kriegsmann M.

Pathology. 2019 Apr;51(3):240-245. doi: 10.1016/j.pathol.2018.11.009. Epub 2019 Feb 21.

PMID:
30798982
7.

BAP1 Loss is a Useful Adjunct to Distinguish Malignant Mesothelioma Including the Adenomatoid-like Variant From Benign Adenomatoid Tumors.

Erber R, Warth A, Muley T, Hartmann A, Herpel E, Agaimy A.

Appl Immunohistochem Mol Morphol. 2019 Jan 11. doi: 10.1097/PAI.0000000000000700. [Epub ahead of print]

PMID:
30640754
8.

Best Practices Recommendations for Diagnostic Immunohistochemistry in Lung Cancer.

Yatabe Y, Dacic S, Borczuk AC, Warth A, Russell PA, Lantuejoul S, Beasley MB, Thunnissen E, Pelosi G, Rekhtman N, Bubendorf L, Mino-Kenudson M, Yoshida A, Geisinger KR, Noguchi M, Chirieac LR, Bolting J, Chung JH, Chou TY, Chen G, Poleri C, Lopez-Rios F, Papotti M, Sholl LM, Roden AC, Travis WD, Hirsch FR, Kerr KM, Tsao MS, Nicholson AG, Wistuba I, Moreira AL.

J Thorac Oncol. 2019 Mar;14(3):377-407. doi: 10.1016/j.jtho.2018.12.005. Epub 2018 Dec 18.

PMID:
30572031
9.

Transbronchial Cryobiopsies for Diagnosing Interstitial Lung Disease: Real-Life Experience from a Tertiary Referral Center for Interstitial Lung Disease.

Wälscher J, Groß B, Eberhardt R, Heussel CP, Eichinger M, Warth A, Lasitschka F, Herth FJF, Kreuter M.

Respiration. 2019;97(4):348-354. doi: 10.1159/000493428. Epub 2018 Dec 14.

PMID:
30554201
10.

Pathways regulating the expression of the immunomodulatory protein glycodelin in non‑small cell lung cancer.

Weber R, Meister M, Muley T, Thomas M, Sültmann H, Warth A, Winter H, Herth FJF, Schneider MA.

Int J Oncol. 2019 Feb;54(2):515-526. doi: 10.3892/ijo.2018.4654. Epub 2018 Dec 5.

11.

Subclonal evolution of pulmonary adenocarcinomas delineated by spatially distributed somatic mitochondrial mutations.

Kazdal D, Harms A, Endris V, Penzel R, Oliveira C, Kriegsmann M, Longuespée R, Winter H, Schneider MA, Muley T, Pfarr N, Weichert W, Stenzinger A, Warth A.

Lung Cancer. 2018 Dec;126:80-88. doi: 10.1016/j.lungcan.2018.10.024. Epub 2018 Oct 29.

PMID:
30527196
12.

Glycodelin as a Serum and Tissue Biomarker for Metastatic and Advanced NSCLC.

Schneider MA, Muley T, Weber R, Wessels S, Thomas M, Herth FJF, Kahn NC, Eberhardt R, Winter H, Heussel G, Warth A, Herold-Mende C, Meister M.

Cancers (Basel). 2018 Dec 4;10(12). pii: E486. doi: 10.3390/cancers10120486.

13.

Targeting LINC00673 expression triggers cellular senescence in lung cancer.

Roth A, Boulay K, Groß M, Polycarpou-Schwarz M, Mallette FA, Regnier M, Bida O, Ginsberg D, Warth A, Schnabel PA, Muley T, Meister M, Zabeck H, Hoffmann H, Diederichs S.

RNA Biol. 2018;15(12):1499-1511. doi: 10.1080/15476286.2018.1553481. Epub 2018 Dec 7.

PMID:
30499379
14.

Tumor Budding and Cell Nest Size Are Highly Prognostic in Laryngeal and Hypopharyngeal Squamous Cell Carcinoma: Further Evidence for a Unified Histopathologic Grading System for Squamous Cell Carcinomas of the Upper Aerodigestive Tract.

Boxberg M, Kuhn PH, Reiser M, Erb A, Steiger K, Pickhard A, Straßen U, Koob I, Kolk A, Warth A, Jesinghaus M, Weichert W.

Am J Surg Pathol. 2019 Mar;43(3):303-313. doi: 10.1097/PAS.0000000000001178.

PMID:
30475254
15.

Insulinoma-associated Protein 1 (INSM1) in Thoracic Tumors is Less Sensitive but More Specific Compared With Synaptophysin, Chromogranin A, and CD56.

Kriegsmann K, Zgorzelski C, Kazdal D, Cremer M, Muley T, Winter H, Longuespée R, Kriegsmann J, Warth A, Kriegsmann M.

Appl Immunohistochem Mol Morphol. 2018 Oct 24. doi: 10.1097/PAI.0000000000000715. [Epub ahead of print]

PMID:
30358615
16.

Molecular signatures in IASLC/ATS/ERS classified growth patterns of lung adenocarcinoma.

Zabeck H, Dienemann H, Hoffmann H, Pfannschmidt J, Warth A, Schnabel PA, Muley T, Meister M, Sültmann H, Fröhlich H, Kuner R, Lasitschka F.

PLoS One. 2018 Oct 23;13(10):e0206132. doi: 10.1371/journal.pone.0206132. eCollection 2018.

17.

Global DNA methylation reflects spatial heterogeneity and molecular evolution of lung adenocarcinomas.

Dietz S, Lifshitz A, Kazdal D, Harms A, Endris V, Winter H, Stenzinger A, Warth A, Sill M, Tanay A, Sültmann H.

Int J Cancer. 2019 Mar 1;144(5):1061-1072. doi: 10.1002/ijc.31939. Epub 2018 Dec 3.

PMID:
30350867
18.

Procedure-Specific Risk Prediction for Recurrence in Patients Undergoing Lobectomy or Sublobar Resection for Small (≤2 cm) Lung Adenocarcinoma: An International Cohort Analysis.

Bains S, Eguchi T, Warth A, Yeh YC, Nitadori JI, Woo KM, Chou TY, Dienemann H, Muley T, Nakajima J, Shinozaki-Ushiku A, Wu YC, Lu S, Kadota K, Jones DR, Travis WD, Tan KS, Adusumilli PS.

J Thorac Oncol. 2019 Jan;14(1):72-86. doi: 10.1016/j.jtho.2018.09.008. Epub 2018 Sep 22.

PMID:
30253972
19.

Computer-Based Intensity Measurement Assists Pathologists in Scoring Phosphatase and Tensin Homolog Immunohistochemistry - Clinical Associations in NSCLC Patients of the European Thoracic Oncology Platform Lungscape Cohort.

Rulle U, Tsourti Z, Casanova R, Deml KF, Verbeken E, Thunnissen E, Warth A, Cheney R, Sejda A, Speel EJ, Madsen LB, Nonaka D, Navarro A, Sansano I, Marchetti A, Finn SP, Monkhorst K, Kerr KM, Haberecker M, Wu C, Zygoura P, Kammler R, Geiger T, Gendreau S, Schulze K, Vrugt B, Wild P, Moch H, Weder W, Ciftlik AT, Dafni U, Peters S, Bubendorf L, Stahel RA, Soltermann A.

J Thorac Oncol. 2018 Dec;13(12):1851-1863. doi: 10.1016/j.jtho.2018.08.2034. Epub 2018 Sep 18.

20.

Digital PCR After MALDI-Mass Spectrometry Imaging to Combine Proteomic Mapping and Identification of Activating Mutations in Pulmonary Adenocarcinoma.

Kazdal D, Longuespée R, Dietz S, Casadonte R, Schwamborn K, Volckmar AL, Kriegsmann J, Kriegsmann K, Fresnais M, Stenzinger A, Sültmann H, Warth A, Kriegsmann M.

Proteomics Clin Appl. 2019 Jan;13(1):e1800034. doi: 10.1002/prca.201800034. Epub 2018 Oct 15.

PMID:
30216696

Supplemental Content

Loading ...
Support Center